For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
KEY FINDINGS
In 2018, the Europe DNA sequencing market captured market share of XX% in the global market. By the end of the forecast period of 2019-2027, the market is expected to rise with 17.32% CAGR and contribute a net revenue share of X%. Significant funding and infrastructure for cancer genomics fields in Europe, is helping to drive the adoption of cancer liquid and tissue biopsy diagnostics which majorly employs sequencing techniques.
MARKET INSIGHTS
Europe enjoys significant funding and infrastructure for cancer genomics, which helps to drive the DNA sequencing market adoption in this region. Large-scale government funding, faster processing techniques and huge pharmaceutical industry investment are driving the U.K market. The country is expected to account for the highest revenue share by the end of the forecast period for the European region. Other significant markets in this region include Germany, Spain, France, Netherlands, Switzerland, and Austria. The Hartwig Medical Foundation is the first national DNA data 'sequencing' center in Netherland which caters to personalized cancer care. Switzerland's first high-throughput DNA sequencing platform, which could well become one of Europe's largest, has opened its doors on Campus Biotech in Geneva. It is increasingly focused on promoting personalized health care and precision medicine across Switzerland.
The process of selective breeding is known to modify the genetic composition of the plants with time. Thus, the ability of DNA markers to advance the precision and efficiency of conservative plant breeding is boosting the DNA sequencing market in Europe.
COMPETITIVE INSIGHTS
Wafergen Bio-Systems, Inc. (merged with Takara Bio), Pacific Biosciences, Appistry Inc., Asuragen, Inc., BGI, F. Hoffmann-La Roche Ltd., Illumina, Adaptive Biotechnologies, Inc., Roche Diagnostics, Spiral Genetics, Inc., Thermo Fisher Scientific, Inc., Ubiquity Genomics, Inc., Agilent Technologies, Inc., Abbott Laboratories, ZS Genetics, Inc. and Cell Microsystems, Inc. are some of the contending market players in Europe for trading the DNA sequencing services and products.